Nuvig Therapeutics Trigger: New CEO, New Pipeline

🚀 Battle Card: Nuvig Therapeutics, Inc.

• David J. Woodhouse, Ph.D., Chief Executive Officer · 🔗 LinkedIn

• New leadership with deep finance, BD and biotech R&D chops signals an aggressive push through multiple Phase 2 trials and platform licensing. This Nuvig Therapeutics, Inc. sales trigger means they’ll be hunting partners to scale NVG-2089. → Source

• Scaling recombinant NVG-2089 production to meet complex Phase 2 & future commercial demand

• Securing strategic partnerships for broader BESTech™ platform indication rollout

• Primary: Clinical Trial Management Software → Accelerate Phase 2 enrollment, compliance & data insights

• Expansion: End-to-End Biologics CDMO Services → Ensure scalable, consistent NVG-2089 supply

• HQ: Menlo Park, CA

• Employees: ≈ 75

• Rev: ≈ $10 M

• Website: nuvigtherapeutics.com

🤼 Competitive Intel

• Veeva Systems — CTMS / EDC
• Unique edge: Industry-specific Vault suite
• Evaluated by Dr. Woodhouse & VP Clinical Ops for seamless integration

• Medidata — CTMS / eCOA
• Unique edge: AI-driven trial analytics
• Evaluated by Head of Clinical for real-time insights

• Catalent — CDMO / Biologics
• Unique edge: End-to-end development to commercial supply
• Evaluated by CFO & Ops for scale reliability

✅ Do-Now Checklist

Next Step

🧠 Copy My Prompt for Personalized Cold Outreach

────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY   = ❑❑
OFFER_BRIEF   = ❑Clinical Trial Management Software❑
PROOF_METRIC  = ❑≈ TBD❑
CTA_STYLE     = ❑quick_call❑
TONE          = ❑punchy❑

────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME        = David
COMPANY     = Nuvig Therapeutics, Inc.
DEPT        = ≈ TBD
SIZE        = 75
BOTTLENECK  = Scaling recombinant NVG-2089 production
EVENT       = CEO appointment
DETAIL      = your CEO appointment
PAIN        = scaling biologics manufacturing
SRC         = http://cts.businesswire.com/ct/CT?id=ftfLlWd9aZbF2NXfwppam3Bd664=&newsLang=en&newsId=20250909619704&div=41152219
SIM_CO      = ≈ TBD
WIN_METRIC  = ≈ TBD
NEXT_SIZE   = ≈ TBD
EMP_EST     = ≈ 75
REV_EST     = ≈ 10 M

────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.

Validate any ≈ guesses via SRC.

EMAIL  (keep breaks):
Subject: 75-person ≈ TBD

David—noticed your ≈ TBD team is ≈ 75.

That’s when Scaling recombinant NVG-2089 production slows growth.

We helped ≈ TBD fix this with Clinical Trial Management Software.

Result: ≈ TBD.  
Quick call?

PS—next bottleneck hits ≈ ≈ TBD.

DM ≤45 words, TONE:
Saw your post about your CEO appointment — scaling biologics manufacturing.  
Clinical Trial Management Software. ≈ TBD.  
Quick chat?